Radium-223 in Biochemically Recurrent Prostate Cancer
NCT04206319
Recruiting
Background: Some men who have been treated for localized prostate cancer with surgery or radiation still show signs of the disease in their blood. This is called biochemically recurrent prostate cancer. Radium-223 is a small molecule. It uses radiation to kill cancer cells and improves survival in advanced prostate cancer. Researchers want to see if it can treat prostate cancer and induced immune changes earlier in the disease when the cancer is only detectable by prostate specific antigen (PSA... Read More
Gender:
MALE
Ages:
Between 18 years and 120 years
Trial Updated:
08/22/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Biochemical Recurrent Prostate Cancer
Register for Updates
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
NCT03841617
Recruiting
Study rationale High risk patients with differentiated thyroid cancer (DTC) require therapy with 131 I under thyroid stimulating hormone (TSH) stimulation. There are two methods of TSH stimulation endogenous by thyroid hormone withdrawal (THW) leading to hypothyroidism and exogenous by injection of human recombinant TSH (rhTSH Thyrogen). The appropriate 131-I activity utilized for treatment is either based on empiric fixed dosage choice or individually determined activity based on 131 I dosimet... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
08/22/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Thyroid Cancer
Register for Updates
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
NCT03412877
Recruiting
Background: A person s tumor is studied for mutations. When cells are found that can attack the mutation in a person s tumor, the genes from those cells are studied to find the parts that make the attack possible. White blood cells are then taken from the person s body, and the gene transfer occurs in a laboratory. A type of virus is used to transfer the genes that make those white blood cells able to attack the mutation in the tumor. The gene transfer therapy is the return of those white blood... Read More
Gender:
ALL
Ages:
Between 18 years and 72 years
Trial Updated:
08/22/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Non-Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer, Endocrine Tumors, Neuroendocrine Tumors, Gastrointestinal/Genitourinary Cancers, Multiple Myeloma
Register for Updates
Study of New Magnetic Resonance Imaging Methods of the Brain
NCT00004577
Recruiting
The purpose of this investigation is to develop improved magnetic resonance imaging (MRI) techniques and hardware for studying brain function. MRI is a diagnostic tool that provides information about brain chemistry and physiology. This study will evaluate new MRI methods for monitoring blood flow to regions of the brain in response to simple tasks. The MRI machine used in this study is more powerful than those in most hospitals, permitting a higher visual resolution. Normal healthy volunteers... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/22/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Healthy, Magnetic Resonance Imaging, Adult, Brain Mapping, fMRI, Healthy Volunteer
Register for Updates
Vascular Disease Discovery Protocol
NCT03538639
Recruiting
Background: Some genetic diseases put increase the risk of heart and blood diseases, which are the number one cause of death and disability in the U.S. Researchers want to study diseases of the heart and/or blood vessels. They want to collect data and specimens from affected people, their family members, and healthy people. Objective: To study diseases of the heart and/or blood vessels. Eligibility: People age 2 and older who may have genetic disease affecting the heart and/or blood vessels... Read More
Gender:
ALL
Ages:
Between 2 years and 100 years
Trial Updated:
08/22/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Vascular Dysfunction, Genetic Mutations, Genetic Predisposition
Register for Updates
Personalized Environment and Genes Study
NCT00341237
Recruiting
Despite the overwhelming focus on genetic and genomic causes of human disease over the past two decades, it has been estimated that genetics is currently known to explain only 20% and 40% of the etiology of common disease. Thus, it is becoming increasingly apparent that human disease is a consequence of both genetic susceptibility and environmental exposures. Importantly, while individuals cannot change their genetic composition, we do have the ability both personally and as a society, to influe... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/22/2025
Locations: NIEHS Clinical Research Unit (CRU), Research Triangle Park, North Carolina
Conditions: Diabetes, Heart Disease, Asthma
Register for Updates
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
NCT04396236
Recruiting
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
08/22/2025
Locations: Central Research Associates, Birmingham, Alabama +149 locations
Conditions: Migraine
Register for Updates
A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
NCT04573140
Recruiting
The primary objective will be to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in (Stratum 1) adult patients with newly diagnosed GBM (MGMT low level or unmethylated in adults only) and (Stratum 2) in pediatric patients with newly diagnosed HGG (pHGG). Funding Source - FDA OOPD
Gender:
ALL
Ages:
4 years and above
Trial Updated:
08/22/2025
Locations: UF Health, Gainesville, Florida
Conditions: Adult Glioblastoma, High Grade Glioma, WHO Grade III or IV Malignant Glioma
Register for Updates
Human Movement Database
NCT00001252
Recruiting
This study will collect information on the different ways people control limb and body movements. This information will be used to develop a database on normal movements and adaptive movements of people who have diseases that affect the way they move. The database will serve as a tool to improve diagnosis and treatment of patients with movement-related problems. Volunteers from one month old to old age who have normal movement patterns or who have developed different ways to perform movement ta... Read More
Gender:
ALL
Ages:
Between 1 month and 99 years
Trial Updated:
08/22/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Movement Disorder
Register for Updates
Cytapheresis of Volunteer Donors
NCT00104325
Recruiting
Background: - National Institute on Aging researchers are looking at studies that require large numbers of white blood cells for lab use. Standard blood samples do not provide enough white blood cells for these studies. Researchers want to use cytapheresis to collect white blood cells from volunteer donors. This procedure can collect larger amounts of white blood cells and reduce the amount of fluid and other cells that are lost. Objectives: - To use cytapheresis to collect white blood cells... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/22/2025
Locations: National Institute of Aging, Clinical Research Unit, Baltimore, Maryland
Conditions: Healthy Volunteers
Register for Updates
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
NCT05271409
Recruiting
The main objective of this study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of an adjudicated MOGAD relapse in the double-blind (DB) treatment period. Participants who experience an adjudicated relapse or complete the DB period can enter open-label extension (OLE) period. After the primary clinical cutoff date (CCOD), additional adolescent participants may be enrolled directly into the OLE period.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/22/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +80 locations
Conditions: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Register for Updates
Chronic Graft-versus-Host Disease in the Oral Cavity of Patients Following Allogeneic Hematopoietic Stem Cell Transplant and Including Healthy Controls
NCT03602599
Recruiting
Background: This study follows people who have had, or will soon have, a transplant using stem cells from another person. This is known as an allogeneic hematopoietic stem cell transplant (HSCT). Graft-versus-host disease (cGVHD) can happen after HSCT. cGVHD can cause mouth problems and more serious issues. Researchers want to study changes in the mouth that might indicate cGVHD. Objective: To identify cGVHD in the mouth and better understand the development, treatment, and progress of post-t... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/22/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Graft Versus Host Disease
Register for Updates